Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination
Front Med
.
2021 Dec;15(6):938-941.
doi: 10.1007/s11684-021-0895-9.
Epub 2021 Sep 30.
Authors
Prathit A Kulkarni
1
2
,
Vinay Prasad
3
Affiliations
1
Infectious Diseases Section, Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA. pakulkar@bcm.edu.
2
Medical Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, 77030, USA. pakulkar@bcm.edu.
3
Department of Epidemiology and Biostatistics, School of Medicine, University of California-San Francisco, San Francisco, CA, 94143, USA.
PMID:
34595694
PMCID:
PMC8482953
DOI:
10.1007/s11684-021-0895-9
No abstract available
MeSH terms
Ad26COVS1
COVID-19*
Humans
SARS-CoV-2
Thrombocytopenia*
Thrombosis* / etiology
Thrombosis* / prevention & control
Vaccination
Substances
Ad26COVS1